CD38

From Wikipedia, the free encyclopedia

Template:Short description Template:Cs1 config An Error has occurred retrieving Wikidata item for infobox CD38 (cluster of differentiation 38), also known as cyclic ADP ribose hydrolase, is a glycoprotein[1] found on the surface of many immune cells (white blood cells), including CD4+, CD8+, B lymphocytes and natural killer cells. CD38 also functions in cell adhesion, signal transduction and calcium signaling.[2]

In humans, the CD38 protein is encoded by the CD38 gene which is located on chromosome 4.[3][4] CD38 is a paralog of CD157, which is also located on chromosome 4 (4p15) in humans.[5]

History

CD38 was first identified in 1980 as a surface marker (cluster of differentiation) of thymus cell lymphocytes.[6][7] In 1992 it was additionally described as a surface marker on B cells, monocytes, and natural killer cells (NK cells).[6] About the same time, CD38 was discovered to be not simply a marker of cell types, but an activator of B cells and T cells.[6] In 1992 the enzymatic activity of CD38 was discovered, having the capacity to synthesize the calcium-releasing second messengers cyclic ADP-ribose (cADPR) and nicotinic acid adenine dinucleotide phosphate (NAADP).[6]

Tissue distribution

CD38 is most frequently found on plasma B cells, followed by natural killer cells, followed by B cells and T cells, and then followed by a variety of cell types.[8]

Function

CD38 can function either as a receptor or as an enzyme.[9] As a receptor, CD38 can attach to CD31 on the surface of T cells, thereby activating those cells to produce a variety of cytokines.[9] CD38 activation cooperates with TRPM2 channels to initiate physiological responses such as cell volume regulation.[10]

CD38 is also a component of the B-cell co-receptor complex, where it associates with CD19. It plays an essential role in regulating B-cell receptor (BCR) signaling, thereby influencing B-cell activation upon antigenic recognition.[11]

CD38 is a multifunctional enzyme that catalyzes the synthesis of ADP ribose (ADPR) (97%) and cyclic ADP-ribose (cADPR) (3%) from NAD+.[12][13] CD38 is thought to be a major regulator of NAD+ levels, its NADase activity is much higher than its function as an ADP-rybosyl-cyclase: for every 100 molecules of NAD+ converted to ADP ribose it generates one molecule of cADPR.[14][12] When nicotinic acid is present under acidic conditions, CD38 can hydrolyze nicotinamide adenine dinucleotide phosphate (NADP+) to NAADP.[12][15]

These reaction products are essential for the regulation of intracellular Ca2+.[16] CD38 occurs not only as an ectoenzyme on cell outer surfaces, but also occurs on the inner surface of cell membranes, facing the cytosol performing the same enzymatic functions.[17]

CD38 is believed to control or influence neurotransmitter release in the brain by producing cADPR.[18] CD38 within the brain enables release of the affiliative neuropeptide oxytocin.[19]

Like CD38, CD157 is a member of the ADP-ribosyl cyclase family of enzymes that catalyze the formation of cADPR from NAD+, although CD157 is a much weaker catalyst than CD38.[20] The SARM1 enzyme also catalyzes the formation of cADPR from NAD+,[17] but SARM1 elevates cADPR much more efficiently than CD38.[21]

Clinical significance

The loss of CD38 function is associated with impaired immune responses, metabolic disturbances, and behavioral modifications including social amnesia possibly related to autism.[16][22]

CD31 on endothelial cells binds to the CD38 receptor on natural killer cells for those cells to attach to the endothelium.[23][24] CD38 on leukocytes attaching to CD31 on endothelial cells allows for leukocyte binding to blood vessel walls, and the passage of leukocytes through blood vessel walls.[5]

The cytokine interferon gamma and the Gram negative bacterial cell wall component lipopolysaccharide induce CD38 expression on macrophages.[24] Interferon gamma strongly induces CD38 expression on monocytes.[16] The cytokine tumor necrosis factor strongly induces CD38 on airway smooth muscle cells inducing cADPR-mediated Ca2+, thereby increasing dysfunctional contractility resulting in asthma.[25]

The CD38 protein is a marker of cell activation. It has been connected to HIV infection, leukemias, myelomas,[26] solid tumors, type II diabetes mellitus and bone metabolism, as well as some genetically determined conditions.

CD38 increases airway contractility hyperresponsiveness, is increased in the lungs of asthmatic patients, and amplifies the inflammatory response of airway smooth muscle of those patients.[13]

Clinical application

CD38 inhibitors may be used as therapeutics for the treatment of asthma.[27]

CD38 has been used as a prognostic marker in leukemia.[28]

Daratumumab (Darzalex) which targets CD38 has been used in treating multiple myeloma.[29][30]

The use of Daratumumab can interfere with pre-blood transfusion tests, as CD38 is weakly expressed on the surface of erythrocytes. Thus, a screening assay for irregular antibodies against red blood cell antigens or a direct immunoglobulin test can produce false-positive results.[31] This can be sidelined by either pretreatment of the erythrocytes with dithiothreitol (DTT) or by using an anti-CD38 antibody neutralizing agent, e.g. DaraEx.

Inhibitors

Aging studies

A gradual increase in CD38 has been implicated in the decline of NAD+ with age.[46][47] Treatment of old mice with a specific CD38 inhibitor, 78c, prevents age-related NAD+ decline.[48] CD38 knockout mice have twice the levels of NAD+ and are resistant to age-associated NAD+ decline,[49] with dramatically increased NAD+ levels in major organs (liver, muscle, brain, and heart).[50] On the other hand, mice overexpressing CD38 exhibit reduced NAD+ and mitochondrial dysfunction.[49]

Macrophages are believed to be primarily responsible for the age-related increase in CD38 expression and NAD+ decline.[51] Cellular senescence of macrophages increases CD38 expression.[51] Macrophages accumulate in visceral fat and other tissues with age, leading to chronic inflammation.[52] The inflammatory transcription factor NF-κB and CD38 are mutually activating.[51] Secretions from senescent cells induce high levels of expression of CD38 on macrophages, which becomes the major cause of NAD+ depletion with age.[53]

Decline of NAD+ in the brain with age may be due to increased CD38 on astrocytes and microglia, leading to neuroinflammation and neurodegeneration.[18]

References

Page Template:Reflist/styles.css has no content.

  1. ^ Page Module:Citation/CS1/styles.css has no content.Orciani M, Trubiani O, Guarnieri S, Ferrero E, Di Primio R (October 2008). "CD38 is constitutively expressed in the nucleus of human hematopoietic cells". Journal of Cellular Biochemistry. 105 (3): 905–12. doi:10.1002/jcb.21887. PMID 18759251. S2CID 44430455.
  2. ^ Page Module:Citation/CS1/styles.css has no content."Entrez Gene: CD38 CD38 molecule".
  3. ^ Page Module:Citation/CS1/styles.css has no content.Jackson DG, Bell JI (April 1990). "Isolation of a cDNA encoding the human CD38 (T10) molecule, a cell surface glycoprotein with an unusual discontinuous pattern of expression during lymphocyte differentiation". Journal of Immunology. 144 (7): 2811–5. doi:10.4049/jimmunol.144.7.2811. PMID 2319135. S2CID 29082806.
  4. ^ Page Module:Citation/CS1/styles.css has no content.Nata K, Takamura T, Karasawa T, Kumagai T, Hashioka W, Tohgo A, et al. (February 1997). "Human gene encoding CD38 (ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase): organization, nucleotide sequence and alternative splicing". Gene. 186 (2): 285–92. doi:10.1016/S0378-1119(96)00723-8. PMID 9074508.
  5. ^ a b Page Module:Citation/CS1/styles.css has no content.Quarona V, Zaccarello G, Chillemi A (2013). "CD38 and CD157: a long journey from activation markers to multifunctional molecules". Cytometry Part B. 84 (4): 207–217. doi:10.1002/cyto.b.21092. hdl:2318/134656. PMID 23576305. S2CID 205732787.
  6. ^ a b c d Page Module:Citation/CS1/styles.css has no content.Lee H, ed. (2002). A Natural History of the Human CD38 Gene. In:Cyclic ADP-Ribose and NAADP. Springer Publishing. doi:10.1007/978-1-4615-0269-2_4. ISBN 978-1-4613-4996-9.
  7. ^ Page Module:Citation/CS1/styles.css has no content.Reinherz EL, Kung PC, Schlossman SF (1980). "Discrete stages of human intrathymic differentiation: analysis of normal thymocytes and leukemic lymphoblasts of T-cell lineage". Proceedings of the National Academy of Sciences of the United States of America. 77 (3): 1588–1592. Bibcode:1980PNAS...77.1588R. doi:10.1073/pnas.77.3.1588. PMC 348542. PMID 6966400.
  8. ^ Page Module:Citation/CS1/styles.css has no content.van de Donk N, Richardson PG, Malavasi F (2018). "CD38 antibodies in multiple myeloma: back to the future". Blood. 131 (1): 13–29. doi:10.1182/blood-2017-06-740944. PMID 29118010.
  9. ^ a b Page Module:Citation/CS1/styles.css has no content.Nooka AK, Kaufman JL, Hofmeister CC, Joseph NS (2019). "Daratumumab in multiple myeloma". Cancer. 125 (14): 2364–2382. doi:10.1002/cncr.32065. PMID 30951198. S2CID 96435958.
  10. ^ Page Module:Citation/CS1/styles.css has no content.Numata T, Sato K, Christmann J, Marx R, Mori Y, Okada Y, et al. (2012). "The ΔC splice-variant of TRPM2 is the hypertonicity-induced cation channel in HeLa cells, and the ecto-enzyme CD38 mediates its activation". J. Physiol. 590 (5): 1121–1138. doi:10.1113/jphysiol.2011.220947. PMC 3381820. PMID 22219339.
  11. ^ Page Module:Citation/CS1/styles.css has no content.Camponeschi A, Kläsener K, et al. (2022). "Human CD38 regulates B cell antigen receptor dynamic organization in normal and malignant B cells". Journal of Experimental Medicine. 219 (9) e20220201. doi:10.1084/jem.20220201. PMC 9280193. PMID 35819358.
  12. ^ a b c Page Module:Citation/CS1/styles.css has no content.Kar A, Mehrotra S, Chatterjee S (2020). "CD38: T Cell Immuno-Metabolic Modulator". Cells. 9 (7): 1716. doi:10.3390/cells9071716. PMC 7408359. PMID 32709019.
  13. ^ a b Page Module:Citation/CS1/styles.css has no content.Guedes A, Dileepan M, Jude JA, Kannan MS (2020). "Role of CD38/cADPR signaling in obstructive pulmonary diseases". Current Opinion in Pharmacology. 51: 29–33. doi:10.1016/j.coph.2020.04.007. PMC 7529733. PMID 32480246.
  14. ^ Page Module:Citation/CS1/styles.css has no content.Braidy N, Berg J, Clement J, Sachdev P (2019). "Role of Nicotinamide Adenine Dinucleotide and Related Precursors as Therapeutic Targets for Age-Related Degenerative Diseases: Rationale, Biochemistry, Pharmacokinetics, and Outcomes". Antioxidants & Redox Signaling. 10 (2): 251–294. doi:10.1089/ars.2017.7269. PMC 6277084. PMID 29634344.
  15. ^ Page Module:Citation/CS1/styles.css has no content.Chini EN, Chini CC, Kato I, Takasawa S, Okamoto H (February 2002). "CD38 is the major enzyme responsible for synthesis of nicotinic acid-adenine dinucleotide phosphate in mammalian tissues". The Biochemical Journal. 362 (Pt 1): 125–30. doi:10.1042/0264-6021:3620125. PMC 1222368. PMID 11829748.
  16. ^ a b c Page Module:Citation/CS1/styles.css has no content.Malavasi F, Deaglio S, Funaro A, Ferrero E, Horenstein AL, Ortolan E, et al. (July 2008). "Evolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathology". Physiological Reviews. 88 (3): 841–86. doi:10.1152/physrev.00035.2007. PMID 18626062.
  17. ^ a b Page Module:Citation/CS1/styles.css has no content.Lee HC, Zhao YJ (2019). "Resolving the topological enigma in Ca 2+ signaling by cyclic ADP-ribose and NAADP". Journal of Biological Chemistry. 294 (52): 19831–19843. doi:10.1074/jbc.REV119.009635. PMC 6937575. PMID 31672920.
  18. ^ a b Page Module:Citation/CS1/styles.css has no content.Guerreiro S, Privat A, Bressac L, Toulorge D (2020). "CD38 in Neurodegeneration and Neuroinflammation". Cells. 9 (2): 471. doi:10.3390/cells9020471. PMC 7072759. PMID 32085567.
  19. ^ Page Module:Citation/CS1/styles.css has no content.Tolomeo S, Chiao B, Lei Z, Chew SH, Ebstein RP (2020). "A Novel Role of CD38 and Oxytocin as Tandem Molecular Moderators of Human Social Behavior". Neuroscience & Biobehavioral Reviews. 115: 251–272. doi:10.1016/j.neubiorev.2020.04.013. PMID 32360414. S2CID 216638884.
  20. ^ Page Module:Citation/CS1/styles.css has no content.Higashida H, Hashii M, Tanaka Y, Matsukawa S (2019). "CD38, CD157, and RAGE as Molecular Determinants for Social Behavior". Cells. 9 (1): 62. doi:10.3390/cells9010062. PMC 7016687. PMID 31881755.
  21. ^ Page Module:Citation/CS1/styles.css has no content.Zhao ZY, Xie XJ, Li WH, Zhao YJ (2016). "A Cell-Permeant Mimetic of NMN Activates SARM1 to Produce Cyclic ADP-Ribose and Induce Non-apoptotic Cell Death". iScience. 15: 452–466. doi:10.1016/j.isci.2019.05.001. PMC 6531917. PMID 31128467.
  22. ^ Page Module:Citation/CS1/styles.css has no content.Higashida H, Yokoyama S, Huang JJ, Liu L, Ma WJ, Akther S, et al. (November 2012). "Social memory, amnesia, and autism: brain oxytocin secretion is regulated by NAD+ metabolites and single nucleotide polymorphisms of CD38". Neurochemistry International. 61 (6): 828–38. doi:10.1016/j.neuint.2012.01.030. hdl:2297/32816. PMID 22366648. S2CID 33172185.
  23. ^ Page Module:Citation/CS1/styles.css has no content.Zambello R, Barilà G, Sabrina Manni S (2020). "NK cells and CD38: Implication for (Immuno)Therapy in Plasma Cell Dyscrasias". Cells. 9 (3): 768. doi:10.3390/cells9030768. PMC 7140687. PMID 32245149.
  24. ^ a b Page Module:Citation/CS1/styles.css has no content.Glaría E, Valledor AF (2020). "Roles of CD38 in the Immune Response to Infection". Cells. 9 (1): 228. doi:10.3390/cells9010228. PMC 7017097. PMID 31963337.
  25. ^ Page Module:Citation/CS1/styles.css has no content.Deshpande DA, Guedes A, Graeff R, Dogan S (2018). "CD38/cADPR Signaling Pathway in Airway Disease: Regulatory Mechanisms". Mediators of Inflammation. 2018 8942042. doi:10.1155/2018/8942042. PMC 5821947. PMID 29576747.
  26. ^ Page Module:Citation/CS1/styles.css has no content.Marlein CR, Piddock RE, Mistry JJ, Zaitseva L, Hellmich C, Horton RH, et al. (January 2019). "CD38-driven mitochondrial trafficking promotes bioenergetic plasticity in multiple myeloma". Cancer Research. 79 (9): 2285–2297. doi:10.1158/0008-5472.CAN-18-0773. PMID 30622116.
  27. ^ Page Module:Citation/CS1/styles.css has no content.Deshpande DA, Guedes AG, Lund FE, Kannan MS (2017). "CD38 in the pathogenesis of allergic airway disease: Potential therapeutic targets". Pharmacology & Therapeutics. 172: 116–126. doi:10.1016/j.pharmthera.2016.12.002. PMC 5346344. PMID 27939939.
  28. ^ Page Module:Citation/CS1/styles.css has no content.Deaglio S, Mehta K, Malavasi F (January 2001). "Human CD38: a (r)evolutionary story of enzymes and receptors". Leukemia Research. 25 (1): 1–12. doi:10.1016/S0145-2126(00)00093-X. PMID 11137554.
  29. ^ Page Module:Citation/CS1/styles.css has no content.McKeage K (February 2016). "Daratumumab: First Global Approval". Drugs. 76 (2): 275–81. doi:10.1007/s40265-015-0536-1. PMID 26729183. S2CID 11977989.
  30. ^ Page Module:Citation/CS1/styles.css has no content.Xia C, Ribeiro M, Scott S, Lonial S (October 2016). "Daratumumab: monoclonal antibody therapy to treat multiple myeloma". Drugs of Today. 52 (10): 551–560. doi:10.1358/dot.2016.52.10.2543308. PMID 27910963.
  31. ^ Page Module:Citation/CS1/styles.css has no content.de Vooght KM, Lozano M, Bueno JL, Alarcon A, Romera I, Suzuki K, et al. (May 2018). "Vox Sanguinis International Forum on typing and matching strategies in patients on anti-CD38 monoclonal therapy: summary". Vox Sanguinis. 113 (5): 492–498. doi:10.1111/vox.12653. PMID 29781081. S2CID 29156699.
  32. ^ Page Module:Citation/CS1/styles.css has no content.Blacher E, Ben Baruch B, Levy A, Geva N, Green KD, Garneau-Tsodikova S, et al. (March 2015). "Inhibition of glioma progression by a newly discovered CD38 inhibitor". International Journal of Cancer. 136 (6): 1422–33. doi:10.1002/ijc.29095. PMID 25053177. S2CID 41844152.
  33. ^ Page Module:Citation/CS1/styles.css has no content.Tarragó MG, Chini CC, Kanamori KS, Warner GM, Caride A, de Oliveira GC, et al. (May 2018). "+ Decline". Cell Metabolism. 27 (5): 1081–1095.e10. doi:10.1016/j.cmet.2018.03.016. PMC 5935140. PMID 29719225.
  34. ^ Page Module:Citation/CS1/styles.css has no content.Kellenberger E, Kuhn I, Schuber F, Muller-Steffner H (July 2011). "Flavonoids as inhibitors of human CD38". Bioorganic & Medicinal Chemistry Letters. 21 (13): 3939–42. doi:10.1016/j.bmcl.2011.05.022. PMID 21641214.
  35. ^ Page Module:Citation/CS1/styles.css has no content.Becherer JD, Boros EE, Carpenter TY, Cowan DJ, Deaton DN, Haffner CD, et al. (September 2015). "Discovery of 4-Amino-8-quinoline Carboxamides as Novel, Submicromolar Inhibitors of NAD-Hydrolyzing Enzyme CD38". Journal of Medicinal Chemistry. 58 (17): 7021–56. doi:10.1021/acs.jmedchem.5b00992. PMID 26267483.
  36. ^ Page Module:Citation/CS1/styles.css has no content.Deaton DN, Haffner CD, Henke BR, Jeune MR, Shearer BG, Stewart EL, et al. (May 2018). "2,4-Diamino-8-quinazoline carboxamides as novel, potent inhibitors of the NAD hydrolyzing enzyme CD38: Exploration of the 2-position structure-activity relationships". Bioorganic & Medicinal Chemistry. 26 (8): 2107–2150. doi:10.1016/j.bmc.2018.03.021. PMID 29576271.
  37. ^ Page Module:Citation/CS1/styles.css has no content.Sepehri B, Ghavami R (January 2019). "Design of new CD38 inhibitors based on CoMFA modelling and molecular docking analysis of 4‑amino-8-quinoline carboxamides and 2,4-diamino-8-quinazoline carboxamides". SAR and QSAR in Environmental Research. 30 (1): 21–38. Bibcode:2019SQER...30...21S. doi:10.1080/1062936X.2018.1545695. PMID 30489181. S2CID 54158219.
  38. ^ Page Module:Citation/CS1/styles.css has no content.Sidiqi MH, Gertz MA (February 2019). "Daratumumab for the treatment of AL amyloidosis". Leukemia & Lymphoma. 60 (2): 295–301. doi:10.1080/10428194.2018.1485914. PMC 6342668. PMID 30033840.
  39. ^ Page Module:Citation/CS1/styles.css has no content."Sarclisa EPAR". European Medicines Agency (EMA). 29 July 2021. Retrieved 29 July 2021.
  40. ^ Page Module:Citation/CS1/styles.css has no content.Raab MS, Engelhardt M, Blank A, Goldschmidt H, Agis H, Blau IW, et al. (May 2020). "MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1-2a trial". The Lancet. Haematology. 7 (5): e381–e394. doi:10.1016/S2352-3026(19)30249-2. PMID 32171061. S2CID 212718499.
  41. ^ Page Module:Citation/CS1/styles.css has no content.Escande C, Nin V, Price NL, Capellini V, Gomes AP, Barbosa MT, et al. (April 2013). "Flavonoid apigenin is an inhibitor of the NAD+ ase CD38: implications for cellular NAD+ metabolism, protein acetylation, and treatment of metabolic syndrome". Diabetes. 62 (4): 1084–1093. doi:10.2337/db12-1139. PMC 3609577. PMID 23172919.
  42. ^ Page Module:Citation/CS1/styles.css has no content.Boslett J, Hemann C, Zhao YJ, Lee HC, Zweier JL (April 2017). "Luteolinidin Protects the Postischemic Heart through CD38 Inhibition with Preservation of NAD(P)(H)". The Journal of Pharmacology and Experimental Therapeutics. 361 (1): 99–108. doi:10.1124/jpet.116.239459. PMC 5363772. PMID 28108596.
  43. ^ Page Module:Citation/CS1/styles.css has no content.Lagu B, Wu X, Kulkarni S, Paul R, Becherer JD, Olson L, et al. (July 2022). "Orally Bioavailable Enzymatic Inhibitor of CD38, MK-0159, Protects against Ischemia/Reperfusion Injury in the Murine Heart". Journal of Medicinal Chemistry. 65 (13): 9418–9446. doi:10.1021/acs.jmedchem.2c00688. PMID 35762533. S2CID 250090300.
  44. ^ Page Module:Citation/CS1/styles.css has no content.Chen PM, Katsuyama E, Satyam A, Li H, Rubio J, Jung S, et al. (June 2022). "CD38 reduces mitochondrial fitness and cytotoxic T cell response against viral infection in lupus patients by suppressing mitophagy". Science Advances. 8 (24) eabo4271. Bibcode:2022SciA....8O4271C. doi:10.1126/sciadv.abo4271. PMC 9200274. PMID 35704572.
  45. ^ Page Module:Citation/CS1/styles.css has no content.Ugamraj HS, Dang K, Ouisse LH, Buelow B, Chini EN, Castello G, et al. (2022). "TNB-738, a biparatopic antibody, boosts intracellular NAD+ by inhibiting CD38 ecto-enzyme activity". mAbs. 14 (1) 2095949. doi:10.1080/19420862.2022.2095949. PMC 9311320. PMID 35867844.
  46. ^ Page Module:Citation/CS1/styles.css has no content.Camacho-Pereira J, Tarragó MG, Chini CC, Nin V, Escande C, Warner GM, et al. (June 2016). "CD38 Dictates Age-Related NAD Decline and Mitochondrial Dysfunction through an SIRT3-Dependent Mechanism". Cell Metabolism. 23 (6): 1127–1139. doi:10.1016/j.cmet.2016.05.006. PMC 4911708. PMID 27304511.
  47. ^ Page Module:Citation/CS1/styles.css has no content.Schultz MB, Sinclair DA (June 2016). "Why NAD(+) Declines during Aging: It's Destroyed". Cell Metabolism. 23 (6): 965–966. doi:10.1016/j.cmet.2016.05.022. PMC 5088772. PMID 27304496.
  48. ^ Page Module:Citation/CS1/styles.css has no content.Tarragó MG, Chini CC, Kanamori KS, Warner GM, Caride A, de Oliveira GC, et al. (May 2018). "A Potent and Specific CD38 Inhibitor Ameliorates Age-Related Metabolic Dysfunction by Reversing Tissue NAD+ Decline". Cell Metabolism. 27 (5): 1081–1095.e10. doi:10.1016/j.cmet.2018.03.016. PMC 5935140. PMID 29719225.
  49. ^ a b Page Module:Citation/CS1/styles.css has no content.Cambronne XA, Kraus WL (2020). "Location, Location, Location: Compartmentalization of NAD + Synthesis and Functions in Mammalian Cells". Trends in Biochemical Sciences. 45 (10): 858–873. doi:10.1016/j.tibs.2020.05.010. PMC 7502477. PMID 32595066.
  50. ^ Page Module:Citation/CS1/styles.css has no content.Kang BE, Choi J, Stein S, Ryu D (2020). "Implications of NAD + boosters in translational medicine". European Journal of Clinical Investigation. 50 (10) e13334. doi:10.1111/eci.13334. PMID 32594513. S2CID 220254270.
  51. ^ a b c Page Module:Citation/CS1/styles.css has no content.Yarbro JR, Emmons RS, Pence BD (2020). "Macrophage Immunometabolism and Inflammaging: Roles of Mitochondrial Dysfunction, Cellular Senescence, CD38, and NAD". Immunometabolism. 2 (3) e200026. doi:10.20900/immunometab20200026. PMC 7409778. PMID 32774895.
  52. ^ Page Module:Citation/CS1/styles.css has no content.Oishi Y, Manabe I (2016). "Macrophages in age-related chronic inflammatory diseases". npj Aging and Mechanisms of Disease. 2 16018. doi:10.1038/npjamd.2016.18. PMC 5515003. PMID 28721272.
  53. ^ Page Module:Citation/CS1/styles.css has no content.Covarrubias AJ, Kale A, Verdin E (2020). "Senescent cells promote tissue NAD+ decline during ageing via the activation of CD38+ macrophages". Nature Metabolism. 2 (11): 1265–1283. doi:10.1038/s42255-020-00305-3. PMC 7908681. PMID 33199924.

Further reading

Page Template:Refbegin/styles.css has no content.

Lua error in package.lua at line 80: module 'Module:Navbox/configuration' not found. Lua error in package.lua at line 80: module 'Module:Navbox/configuration' not found. Lua error in package.lua at line 80: module 'Module:Navbox/configuration' not found.

Retrieved from "https://cosmopedia.co/index.php?title=CD38&oldid=1736498"